Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response

Acta Haematologica

Volumn 124, Issue 1, 2010, Pages 46-48

  Breccia, Massimo ^a,b   Loglisci, Giuseppina ^a   Salaroli, Adriano ^a   Cannella, Laura ^a   Santopietro, Michelina ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Department of Human Biotechnologies and Hematology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIBIOTIC AGENT; DEFERASIROX; ERYTHROPOIETIN; FERRITIN; BENZOIC ACID DERIVATIVE; HEMOGLOBIN; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BLAST CELL; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; FEVER; GALLSTONE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RASH; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION; BLOOD; BLOOD TRANSFUSION; DRUG EFFECT; ERYTHROID CELL; MIDDLE AGED;

BENZOIC ACIDS; BLOOD TRANSFUSION; ERYTHROID CELLS; FERRITINS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TRIAZOLES;

EID: 77954253063     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314961     Document Type: Article

References (11)

1. Cappellini MD, Pattoneri P: Oral iron chelators. Annu Rev Med 2009; 60: 25-38.
2. List A, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa EC: Two-year analysis of efficacy and safety of deferasirox (Exjade) treatment in myelodysplastic syndrome patients enrolled in the US03 study. Blood 2009; 114: 3829.
3. Gattermann N, Schmid M, Della Porta M, Taylor K, Seymour JF, Habr D, Domokos G, Hmissi A, Guerci-Bresler A, Rose C: Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood 2008; 112: 633.
4. Bennett JM: Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83: 858-861.
5. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007; 78: 540-542.
6. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G: Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120: 70-74.
7. Capalbo S, Spinosa G, Franzese MG, Palumbo G: Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements. Acta Haematol 2009; 121: 19-20.
8. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P: Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010; 34: 864-870.
9. Jensen PD, Heickendorff L, Pedersen B, Bendix- Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegard J: The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-299.
10. Messa E, De Filippi I, Roetto A, Messa F, Arruga F, Carturan S, Rosso V, Bracco E, Cilloni D, Saglio G: Deferasirox is the only iron chelator acting as a potent NF-kB inhibitor in myelodysplastic syndromes. Blood 2008; 112: 2671.
11. Rachmilewitz E, Merkel D, Ghoti H, Amer J, Nagler A, Perez-Avraham G, Grisariu S, Naparstek E, Ackerstein A, Fibach E: Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood 2008; 112: 2675.